Journal of Alzheimer's Disease最新文献

The association between measures of sleepiness and subjective cognitive decline symptoms in a diverse population of cognitively normal older adults.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-04-01 DOI: 10.1177/13872877251331237

Anthony Q Briggs, Carolina Boza-Calvo, Mark A Bernard, Henry Rusinek, Rebecca A Betensky, Arjun V Masurkar

引用次数: 0

Unraveling the genetic underpinnings of mitochondrial traits and associated circulating inflammatory proteins in Alzheimer's disease: Mitochondrial HtrA2-T cell CD5 negative axis.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-04-01 DOI: 10.1177/13872877251329517

Yixi Wang, Zhuokai Wu, Yiheng Zheng, Haimeng Wang, Bin Cheng, Juan Xia

{"title":"Unraveling the genetic underpinnings of mitochondrial traits and associated circulating inflammatory proteins in Alzheimer's disease: Mitochondrial HtrA2-T cell CD5 negative axis.","authors":"Yixi Wang, Zhuokai Wu, Yiheng Zheng, Haimeng Wang, Bin Cheng, Juan Xia","doi":"10.1177/13872877251329517","DOIUrl":"https://doi.org/10.1177/13872877251329517","url":null,"abstract":"BackgroundPrevious studies with limited sample sizes have indicated a link between mitochondrial traits, inflammatory proteins, and Alzheimer's disease. The exact causality and their mediation relationships remain unclear.ObjectiveOur study aimed to delve into the genetic underpinnings of mitochondrial function and circulating inflammatory proteins in the pathogenesis of Alzheimer's disease.MethodsWe leveraged aggregated data from the largest genome-wide association study, including 69 mitochondrial traits, 91 circulating inflammatory proteins, and Alzheimer's disease. Bidirectional mendelian randomization (MR) analyses were performed to investigate their primary causal relationships. Thereafter a two-step MR mediation analysis was utilized to clarify the modulating effects of inflammatory proteins on mitochondria and Alzheimer's disease.ResultsOur study identified mitochondrial phenylalanine-tRNA ligase and 4-hydroxy-2-oxoglutarate aldolase as risk factors for Alzheimer's disease, and serine protease HtrA2 and carbonic anhydrase 5A as protective factors against Alzheimer's disease. Four inflammatory proteins (T-cell surface glycoprotein CD5, C-X-C motif chemokine 11, TGF-α, and TNF-related apoptosis-inducing ligand) played protective roles against Alzheimer's disease. Axin-1 and IL-6 increased the risk of Alzheimer's disease. Furthermore, T-cell surface glycoprotein CD5 was found to be a significant mediator between mitochondrial serine protease HTRA2 and Alzheimer's disease with the two-step MR method, accounting for 10.83% of the total effect.ConclusionsOur study emphasized mitochondrial HtrA2-T cell CD5 as a negative axis in Alzheimer's disease, offering novel perspectives on its etiology, pathogenesis, and treatment.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251329517"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-04-01 DOI: 10.1177/13872877251329394

Patricia A Deverka, Jalayne J Arias, Grace A Lin, Jessica Zwerling, Kathryn A Phillips

{"title":"Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.","authors":"Patricia A Deverka, Jalayne J Arias, Grace A Lin, Jessica Zwerling, Kathryn A Phillips","doi":"10.1177/13872877251329394","DOIUrl":"https://doi.org/10.1177/13872877251329394","url":null,"abstract":"BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests.ObjectiveTo describe considerations for payer coverage of AD BBMTs that would need to be addressed to facilitate timely diagnosis and equitable patient access if clinical utility is demonstrated.MethodsWe performed a targeted literature review to characterize predictable coverage barriers for BBMTs and inform the development of an interview guide. We conducted semi-structured interviews with clinicians, researchers, test developers, and a patient advocate and former payer (N = 12) to assess the barriers and refine the proposed key considerations for obtaining payer coverage.ResultsStakeholders noted that payers will require evidence of clinical validity and utility of BBMTs as part of their coverage determinations contingent on the specific indication for testing, with insufficient evidence for screening applications currently. Stakeholders also agreed that there are evidence gaps for use of BBMTs in patients from ethnic and racial minority communities that must be addressed. Given the shortage of memory specialists, stakeholders noted that limiting testing coverage authorization to specialists could be harmful to patients, particularly the underserved. Interviewees also agreed that patients with mild cognitive impairment or early-stage AD could benefit from earlier diagnosis to avoid progressing to moderate disease and limiting eligibility for new disease-modifying therapies.ConclusionsIf BBMTs meet criteria for clinical utility, anticipating and planning for coverage and reimbursement before widespread implementation will be critical to ensuring broad, equitable access to BBMTs.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251329394"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of Dendropanax morbiferus on cognitive function and cerebral cortical thickness: A randomized, double-blind, placebo-controlled trial.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-04-01 DOI: 10.1177/13872877251328941

Chaewon Suh, Shinhye Kim, Yoonji Joo, Eunji Ha, Youngeun Shim, Hyeonji Lee, Yejin Kim, Sujung Yoon

{"title":"The effects of Dendropanax morbiferus on cognitive function and cerebral cortical thickness: A randomized, double-blind, placebo-controlled trial.","authors":"Chaewon Suh, Shinhye Kim, Yoonji Joo, Eunji Ha, Youngeun Shim, Hyeonji Lee, Yejin Kim, Sujung Yoon","doi":"10.1177/13872877251328941","DOIUrl":"https://doi.org/10.1177/13872877251328941","url":null,"abstract":"BackgroundEarly intervention for subjective cognitive decline (SCD) is becoming increasingly important to prevent progression to Alzheimer's disease (AD). Despite the promising results observed in animal models of AD, the neuroprotective and cognitive-enhancing effects of Dendropanax morbiferus (DM) still need to be evaluated in individuals with cognitive decline.ObjectiveThis 12-week, randomized, double-blind, placebo-controlled trial assessed the effects of DM leaf extracts on cognitive function in 85 individuals with SCD (KCT0006329, registered on July 7, 2021).MethodsParticipants were randomly assigned to either the DM (n = 43) or the placebo (n = 42) group. Cognitive functions, including attention and memory, were assessed at baseline, 8 weeks, and 12 weeks. High-resolution T1-weighted magnetic resonance imaging was performed at the beginning and end of the study to evaluate cortical thickness. Changes in cognition and cortical thickness and their associations were evaluated.ResultsThe results demonstrated significant improvements in attention (p = 0.014), memory (p = 0.037), and global cognitive function (p = 0.001) in the DM group compared to the placebo group, accompanied by increased cortical thickness in the left lingual gyrus/cuneus (corrected p < 0.05). Furthermore, in the DM group, increased cortical thickness in this region was correlated with both memory (r = 0.422, p = 0.016) and global cognitive functions (r = 0.471, p = 0.007). DM was well-tolerated, with no adverse events reported.ConclusionsThese findings suggest that DM may possess cognitive-enhancing properties for individuals with SCD.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251328941"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

One-year exercise improves cognition and fitness and decreases vascular stiffness and reactivity to CO2 in amnestic mild cognitive impairment.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-31 DOI: 10.1177/13872877251325575

Suhaas Penukonda, Srivats Srinivasan, Takashi Tarumi, Tsubasa Tomoto, Min Sheng, C Munro Cullum, Rong Zhang, Hanzhang Lu, Binu P Thomas

{"title":"One-year exercise improves cognition and fitness and decreases vascular stiffness and reactivity to CO2 in amnestic mild cognitive impairment.","authors":"Suhaas Penukonda, Srivats Srinivasan, Takashi Tarumi, Tsubasa Tomoto, Min Sheng, C Munro Cullum, Rong Zhang, Hanzhang Lu, Binu P Thomas","doi":"10.1177/13872877251325575","DOIUrl":"https://doi.org/10.1177/13872877251325575","url":null,"abstract":"BackgroundAmnestic mild cognitive impairment (aMCI) is often a precursor stage to Alzheimer's disease (AD). Aerobic exercise (AE) has received increasing attention in the prevention of AD. While there is some evidence that it improves neurocognitive function in older individuals, the effect of exercise in the long-term is not well understood.ObjectiveTo assess the effect of long-term exercise on cognition, fitness, vascular stiffness, and cerebrovascular reactivity (CVR).MethodsIn this prospective clinical trial, 27 aMCI participants were enrolled into two groups and underwent 12 months of intervention. One group (n = 11) underwent AE training (6M/5F, age = 66.2 years), and the control group (n = 16) performed stretch training (ST group, 9M/7F, age = 66.4 years). Both groups performed training three times per week with duration and intensity gradually increased over time. CVR was measured at pre- and post-training using blood-oxygenation-level-dependent MRI.ResultsIn the AE group, aerobic fitness improved (p = 0.034) and carotid artery stiffness decreased (p = 0.005), which was not observed in the ST group. In all participants, decreases in carotid artery stiffness were associated with increases in aerobic fitness (p = 0.043). The AE group displayed decreases in CVR in the anterior cingulate cortex and middle frontal gyrus (p < 0.05, FWE corrected); the ST group did not show significant changes in CVR. Several measures of cognition (i.e., inhibition and delayed recall), neuropsychiatric symptoms, and functional status ratings improved only in the AE group.ConclusionsThese results suggest that AE may alter cerebral hemodynamics in patients with aMCI which may improve cognitive, psychological, and functional status.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251325575"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing patterns of impairment in social cognition between young-onset and late-onset Alzheimer's disease.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-28 DOI: 10.1177/13872877251323046

Tatiana Belfort, Marcela Lima Nogueira, Julia Gaigher, Rogeria Rangel, Natalie de Souza, Marcia Cristina Nascimento Dourado

{"title":"Comparing patterns of impairment in social cognition between young-onset and late-onset Alzheimer's disease.","authors":"Tatiana Belfort, Marcela Lima Nogueira, Julia Gaigher, Rogeria Rangel, Natalie de Souza, Marcia Cristina Nascimento Dourado","doi":"10.1177/13872877251323046","DOIUrl":"https://doi.org/10.1177/13872877251323046","url":null,"abstract":"BackgroundYoung-onset Alzheimer's disease (YOAD) is defined as when the disease starts before 65 years old. Compared with late-onset AD (LOAD), the progression is faster and more aggressive. However, the impact on social cognition deficits may not follow the same clear pattern.ObjectiveThe present study aims to investigate the relationship between social cognition, global cognition, and other clinical variables in people with YOAD and LOAD and their caregivers.MethodsUsing a cross-sectional design, we included 48 people with YOAD and 118 with LOAD, and their caregivers. We assessed social cognition, global cognition, quality of life, dementia severity, mood, functionality, neuropsychiatric symptoms, and caregiver burden.ResultsThe YOAD group was more impaired in general cognition (p = 0.002, d = 0.06), had a worse quality of life (p = 0.036, d = 0.36), and presented more neuropsychiatric symptoms (p = 0.044, d = 0.35). However, social cognition did not exhibit the same disease progression and showed no difference when compared with the reports of their caregivers or with individuals with LOAD. The multifactorial regression analyses showed that functionality was related to social cognition impairment in YOAD (p = 0.035), and LOAD (p = 0.001).ConclusionsOur study found that people diagnosed with YOAD showed more global cognitive impairment but maintained social and emotional functioning.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251323046"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-28 DOI: 10.1177/13872877251329439

Yanyu Zhai, Kaili Lu, Yuan Yuan, Ziyao Zhang, Lixia Xue, Fei Zhao, Xiaofeng Xu, Hongmei Wang

{"title":"Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.","authors":"Yanyu Zhai, Kaili Lu, Yuan Yuan, Ziyao Zhang, Lixia Xue, Fei Zhao, Xiaofeng Xu, Hongmei Wang","doi":"10.1177/13872877251329439","DOIUrl":"https://doi.org/10.1177/13872877251329439","url":null,"abstract":"BackgroundAlzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide, have shown positive effects on promoting the cognitive function. However, research about the mechanism of semaglutide as a therapeutic intervention in AD is sparse.ObjectiveThis study was to investigate the therapeutic efficacy of semaglutide in a transgenic mouse model of AD pathology and explored the detailed mechanism by semaglutide modulated neuroinflammatory processes.MethodsMale amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mice were treated with semaglutide or vehicle for 8 weeks. Morris water maze test was used to assess the therapeutic efficacy of semaglutide on recognition function. Pathology analysis was performed to detect the deposition of amyloid plaques. High-throughput sequencing analysis was applied to specify the mechanism. Microglia and astrocyte activation were assessed with immunofluorescent staining. Inflammation cytokine levels were evaluated with enzyme-linked immunosorbent assay (ELISA). Related proteins and pathway were evaluated with western blot.ResultsSemaglutide treatment attenuated Aβ accumulation and enhanced cognitive function in APP/PS1 transgenic mice. Through transcriptomic profiling, immunohistochemical staining, and ELISA, semaglutide was substantiated to inhibit the overactivation of microglia and astrocytes, as well as to curtail the secretion of inflammatory mediators. Furthermore, semaglutide robustly activated AMP-activated protein kinase (AMPK) and suppressed the toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling cascade, thus reducing the Aβ deposition and dampening the inflammatory cascade.ConclusionsThe results demonstrated that semaglutide mitigated neuroinflammation and decelerated the advance of AD in APP/PS1 transgenic mice.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251329439"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gamma oscillation modulation for cognitive impairment: A systematic review.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-28 DOI: 10.1177/13872877251328698

Emanuela Bartolini, Adolfo Di Crosta, Pasquale La Malva, Anna Marin, Irene Ceccato, Giulia Prete, Nicola Mammarella, Alberto Di Domenico, Rocco Palumbo

{"title":"Gamma oscillation modulation for cognitive impairment: A systematic review.","authors":"Emanuela Bartolini, Adolfo Di Crosta, Pasquale La Malva, Anna Marin, Irene Ceccato, Giulia Prete, Nicola Mammarella, Alberto Di Domenico, Rocco Palumbo","doi":"10.1177/13872877251328698","DOIUrl":"https://doi.org/10.1177/13872877251328698","url":null,"abstract":"BackgroundGamma oscillation modulation has emerged as a potential non-invasive treatment to counteract cognitive impairment in Alzheimer's disease (AD) and mild cognitive impairment (MCI). Non-invasive brain stimulation techniques like transcranial alternating current stimulation (tACS), gamma sensory stimulation (GSS), and transcranial magnetic stimulation (TMS) show promise in supporting specific cognitive functions.ObjectiveTo review and evaluate the efficacy of gamma oscillation modulation techniques in benefiting cognitive functions among individuals with AD and MCI.MethodsA systematic review was conducted, analyzing studies from 2015 to 2023 across databases such as PubMed, Web of Science, and Scopus. Inclusion criteria focused on studies involving tACS, GSS, or TMS applied to older adults with MCI or AD. A total of 438 articles were screened, of which 10 met the eligibility criteria.ResultsFindings suggest that gamma tACS, especially targeting the precuneus and dorsolateral prefrontal cortex, benefits episodic memory and cognitive performance. GSS also showed potential in supporting memory and attention, while TMS exhibited inconsistent but promising results when applied to the angular gyrus. However, heterogeneity in study designs and small sample sizes limit the generalizability of these outcomes.ConclusionsGamma oscillation modulation offers potential cognitive benefits for patients with AD and MCI, particularly in memory support. Further studies with larger samples and well-designed protocols are needed to confirm its therapeutic efficacy and optimize intervention parameters.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251328698"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prevalence of mild behavioral impairment in older adults with mild cognitive impairment: A systematic review and meta-analysis.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-28 DOI: 10.1177/13872877251328712

Yan Zhao, Chang Tan, Yingjing Lu, Yingling Ge, Na Zhao, Yajie Tian, Liuyang Hui, Xiaobei Feng, Zihan Liu, Sha Li, Huixian Cui

{"title":"The prevalence of mild behavioral impairment in older adults with mild cognitive impairment: A systematic review and meta-analysis.","authors":"Yan Zhao, Chang Tan, Yingjing Lu, Yingling Ge, Na Zhao, Yajie Tian, Liuyang Hui, Xiaobei Feng, Zihan Liu, Sha Li, Huixian Cui","doi":"10.1177/13872877251328712","DOIUrl":"https://doi.org/10.1177/13872877251328712","url":null,"abstract":"BackgroundMild behavioral impairment is a neurobehavioral symptom characterized by the onset of a new and persistent neuropsychiatric syndrome. Patients with co-occurring mild behavioral impairment and mild cognitive impairment have the relatively highest probability of developing dementia than sick mild behavioral impairment or mild cognitive impairment alone.ObjectiveThis study aimed to determine the currently available best estimate of mild behavioral impairment prevalence and clarify the reasons for the difference in estimates.MethodsData were retrieved and collected from five electronic databases. Two reviewers independently appraised the methodological quality of included studies. Heterogeneity was assessed by using the I² statistic and random effects models were employed. Sources of heterogeneity were investigated by subgroup analysis and meta-regression. All statistical analyses were conducted by Stata.ResultsA total of 23 reports involving 5397 participants were included in this systematic review. The pooled effect size for the overall mild behavioral impairment was 52% (95%CI 42-62%). In the subgroup analysis and regression analysis, we found that study type, study area, assessment tools, and study subject gender could explain part of the source of heterogeneity.ConclusionsThe results of this review suggest that 52% with mild cognitive impairment combined with mild behavioral impairment; there is a close relationship between the two. Future studies should pay more attention to the underlying mechanism between the two and provide a more scientific basis for early discrimination of clinical dementia and Alzheimer's disease.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251328712"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex differences on tau, astrocytic, and neurodegenerative plasma biomarkers.

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-03-28 DOI: 10.1177/13872877251329468

Jacob Labonte, Michael A Sugarman, Erika Pettway, Henrik Zetterberg, Kaj Blennow, Nicholas J Ashton, Thomas K Karikari, Hugo J Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N Palmisano, Eric G Steinberg, Irene Simkin, Lindsay A Farrer, Gyungah R Jun, Katherine W Turk, Andrew E Budson, Maureen K O'Connor, Rhoda Au, Lee E Goldstein, Robert A Stern, Thor D Stein, Ann C McKee, Wei Qiao Qiu, Jesse Mez, Sarah J Banks, Michael L Alosco

{"title":"Sex differences on tau, astrocytic, and neurodegenerative plasma biomarkers.","authors":"Jacob Labonte, Michael A Sugarman, Erika Pettway, Henrik Zetterberg, Kaj Blennow, Nicholas J Ashton, Thomas K Karikari, Hugo J Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N Palmisano, Eric G Steinberg, Irene Simkin, Lindsay A Farrer, Gyungah R Jun, Katherine W Turk, Andrew E Budson, Maureen K O'Connor, Rhoda Au, Lee E Goldstein, Robert A Stern, Thor D Stein, Ann C McKee, Wei Qiao Qiu, Jesse Mez, Sarah J Banks, Michael L Alosco","doi":"10.1177/13872877251329468","DOIUrl":"10.1177/13872877251329468","url":null,"abstract":"BackgroundSex differences have consistently been identified on autopsy, neuroimaging, and cerebrospinal fluid outcomes related to Alzheimer's disease (AD), but the exact mechanisms for these associations are unclear. Blood-based biomarkers are practical alternatives for the investigation of mechanisms of AD, in addition to accurate disease detection and monitoring.ObjectiveThe objective of this study was to examine sex differences across a panel of blood-based plasma biomarkers in participants with and without cognitive impairment due to AD.MethodsPlasma samples were collected from 567 participants from across the AD diagnostic continuum (i.e., normal cognition (NC), mild cognitive impairment (MCI), and dementia) and analyzed for glial fibrillary acidic protein (GFAP), neurofilament light (NfL), phosphorylated tau at threonine 181 (p-tau181), and total tau (t-tau). Baseline and longitudinal analyses evaluated for any significant associations between sex and AD-related plasma biomarkers.ResultsFemales were found to have higher plasma GFAP compared to males at baseline regardless of cognitive diagnosis. Among those with AD dementia, females were also found to have higher NfL levels compared to males. Longitudinal analyses found that higher plasma NfL at baseline was associated with an increased risk of worsening AD dementia status only in females. No significant findings were observed for p-tau181 or t-tau.ConclusionsThis study found significant sex differences in plasma biomarkers of GFAP and NfL. Further research is needed to better understand the underlying mechanisms mediating these differences.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251329468"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0